Eyenovia (NSDQ:EYEN) announced today that it partnered with Eversana to help commercialize MydCombi if it earns U.S. approval.
MydCombi is a fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing in an effort to improve the patient experience. The FDA earlier this month accepted Eyenovia’s New Drug Application for MydCombi.
The therapeutic is delivered through Eyenovia’s proprietary Optejet dispenser, which ensures consistent and easy application of two mydriatic medications in a quick, touchless micro-mist form. Optejet is designed with no protruding parts to prevent the accidental touching of the ocular surface.
Eyenovia said MydCombi, if approved by the FDA, would be the first microdosed ocular therapeutic applied with a high-precision smart delivery system. The company anticipates the potential approval to come in the fourth quarter of this year.
Under the commercialization agreement, Eversana will serve as Eyenovia’s exclusive distributor for all customers in the U.S., with responsibilities centered around accepting and managing orders, payments and the shipping of MydCombi to eye care offices throughout the U.S., according to a news release.
Eversana is also slated to establish an Eyenovia e-commerce platform to collect and analyze sales data and provide relevant analytics that will influence Eyenovia’s commercial strategy.
“Eyenovia is striving to make the MydCombi launch efficient and seamless for its eye care provider customers,” Eyenovia COO Michael Rowe said in the release. “Eversana has an exemplary track record for customer service and commercial excellence. Through this partnership, launch and distribution activities that would typically require an infrastructure build will be managed by Eversana, a strategy we anticipate will keep costs well below what is typical in ophthalmology.”
“We believe in MydCombi’s potential to provide patients clinical benefits and a more comfortable experience during eye exams,” Eversana CEO Jim Lang added. “With this collaboration, we look forward to contributing our expertise for a successful launch and roll-out of this valuable product to Eyenovia’s customers.”
